search
Bioconjugates are hybrid molecules that combine a biologic, such as an antibody, with a small molecule payload to create targeted therapies. These constructs, including antibody-drug conjugates (ADCs), leverage the specificity of biologics and the potency of small molecules, enabling more precise treatment of complex diseases like cancer. Developing these molecules requires advanced bioconjugate chemistry and expertise in both biologic and small molecule drug development.
Jan 05, 2026
Modern drug discovery and drug development are becoming increasingly complex, requiring precise measurement, analysis, and interpretation of biological data at every stage. Bioanalytical services provide the tools, expertise, and infrastructure to generate accurate, reproducible results that guide critical decisions in drug development solutions and integrated drug discovery programs.
Dec 26, 2025
Antibody-drug conjugates (ADCs) have emerged as one of the most transformative modalities in oncology, combining the precision of targeted biologics with the potency of cytotoxic drugs. As the demand for safer, more effective cancer therapies accelerates, ADC pharma is experiencing rapid growth – driven by scientific advances, new therapeutic applications, and increasingly sophisticated development strategies.
Dec 23, 2025
Active Pharmaceutical Ingredients (APIs) are the foundation of every medicine, making API manufacturing a critical part of drug development. As specialized technologies like biologics and high potency APIs (HPAPIs) increase the complexity of pipelines, pharma companies need reliable, expert partners to deliver safe, scalable, and compliant production.
Dec 19, 2025
As drug development becomes more complex, the pharmaceutical industry increasingly relies on specialized partners to keep programs moving efficiently. This shift has elevated the role of CDMO pharma, the contract development and manufacturing organization (CDMO) sector that supports innovators throughout the drug pipeline.
Dec 15, 2025
